These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18193497)

  • 41. Incidence of transmitted antiretroviral drug resistance in treatment-naive HIV-1-infected persons in a large South Central United States clinic.
    Kleyn TJ; Liedtke MD; Harrison DL; Lockhart SM; Salvaggio MR; Ripley TL; Rathbun RC
    Ann Pharmacother; 2014 Apr; 48(4):470-5. PubMed ID: 24473489
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy.
    Springer SA; Chen S; Altice F
    AIDS Care; 2009 Aug; 21(8):976-83. PubMed ID: 20024753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy.
    Ing EC; Bae JW; Maru DS; Altice FL
    AIDS Behav; 2013 Jan; 17(1):113-21. PubMed ID: 22105340
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antiretroviral resistance, genotypic characterization and origin of Human Immunodeficiency Virus among the infected wives of Intravenous drug users in Manipur.
    Sharma AL; Singh TR; Singh LS
    Sci Rep; 2018 Oct; 8(1):15183. PubMed ID: 30315192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Investigation of HIV-1 primary drug resistance mutations in antiretroviral therapy-naive cases].
    Yalçınkaya T; Köse S
    Mikrobiyol Bul; 2014 Oct; 48(4):585-95. PubMed ID: 25492654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
    Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
    HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey.
    Steegen K; Carmona S; Bronze M; Papathanasopoulos MA; van Zyl G; Goedhals D; MacLeod W; Sanne I; Stevens WS
    PLoS One; 2016; 11(12):e0166305. PubMed ID: 27907009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effectiveness of first-line antiretroviral therapy and acquired drug resistance among HIV-1-infected children in India.
    Shet A; Neogi U; Sahoo PN; De Costa A
    Pediatr Infect Dis J; 2013 May; 32(5):e227-9. PubMed ID: 23249907
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western Europe.
    Rahim S; Fredrick LM; da Silva BA; Bernstein B; King MS
    HIV Clin Trials; 2009; 10(2):94-103. PubMed ID: 19487179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Short communication: east meets west: a description of HIV-1 drug resistance mutation patterns of patients failing first line therapy in PEPFAR clinics from Uganda and Nigeria.
    Crawford KW; Wakabi S; Kibuuka H; Magala F; Keshinro B; Okoye I; Akintunde E; Hamm TE
    AIDS Res Hum Retroviruses; 2014 Aug; 30(8):796-9. PubMed ID: 24798614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Short communication: low prevalence of genotypic drug resistance mutations among antiretroviral-naive HIV type 1 patients in Malaysia.
    Tee KK; Kamarulzaman A; Ng KP
    AIDS Res Hum Retroviruses; 2006 Feb; 22(2):121-4. PubMed ID: 16478392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
    Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.
    Muri L; Gamell A; Ntamatungiro AJ; Glass TR; Luwanda LB; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E;
    AIDS; 2017 Jan; 31(1):61-70. PubMed ID: 27677163
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique.
    Bila DC; Boullosa LT; Vubil AS; Mabunda NJ; Abreu CM; Ismael N; Jani IV; Tanuri A
    PLoS One; 2015; 10(7):e0130580. PubMed ID: 26151752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    Villabona-Arenas CJ; Vidal N; Guichet E; Serrano L; Delaporte E; Gascuel O; Peeters M
    AIDS; 2016 Nov; 30(17):2577-2589. PubMed ID: 27603287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.